Brief: Mesoblast Says US FDA Accepts BLA Resubmission For Remestemcel-L
23/07/2024 11:15
July 23 (Reuters) - Mesoblast Ltd MSB.AX :
* US FDA ACCEPTS MESOBLAST'S BLA RESUBMISSION FOR
REMESTEMCEL-L
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil